Halozyme will repay in full $250 million term loan due 2026

Chicago, Aug. 18 – Halozyme Therapeutics Inc. said that it will use the proceeds from a recent convertible note sale to repay in full its $250 million term loan due 2026, according to an 8-K filed with the Securities and Exchange Commission.

The company raised $720 million from a new offering of 1% convertible bonds with a six-year tenor.

The company entered into a credit agreement on May 24 for a $350 million revolver and a $250 million term loan due Nov. 30, 2026, according to the Prospect News archive.

Halozyme is a San Diego-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.